Increlex (mecasermin)

pCPA File Number: 21738

Negotiation Status:

Concluded with an LOI

Indication(s):

Severe Primary Insulin-like Growth Factor-1 Deficiency

Sponsor/Manufacturer:

Ipsen Biopharmaceuticals Canada, Inc.

CDA-AMC Project Number:

SR0692-000

pCPA Engagement Letter Issued:

2022-06-13

Negotiation Process Concluded:

2023-02-06